Drug Trial Radar · NCT02208063
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
Last checked: Nov 20, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
121
Actual
Start
Dec 2014
Primary completion
Apr 12, 2018
Study completion Apr 12, 2018
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Conditions
- Bacteremia
Interventions
TelavancinDrug
VancomycinDrug
DaptomycinDrug
Synthetic penicillinDrug
CefazolinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)Time frame: Up to 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Remington-Davis Clinical Research
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.